SOLVE FSHD, a venture-philanthropic organization catalyzing the pace of innovation to accelerate a cure for facioscapulohumeral muscular dystrophy (FSHD), announced today an investment of US$10M million in Vita Therapeutics; a cell engineering company harnessing the power of genetics to develop novel cellular therapies to treat muscular dystrophies and solid tumours.

We are a team of dedicated scientists striving to advance treatments in multiple indications in our cell therapy platform.  Our mission is to utilize the power of genetics to deliver life-transformative cell therapies by unlocking the potential of engineered cellular medicine.



Solve Fshd Invests Us$10 Million In Vita Therapeutics

Description

Company Information

Related People

Funding Insights

Solve Fshd Invests Us$10 Million In Vita Therapeutics

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information